Evidence map›Paper›PMID 39125591›Full record

ArticleInternational journal of molecular sciences2024

Upregulated Nuclear Expression of Soluble Epoxide Hydrolase Predicts Poor Outcome in Breast Cancer Patients: Importance of the Digital Pathology Approach.

Mayra Montecillo-Aguado, Giovanny Soca-Chafre, Gabriela Antonio-Andres, Mario Morales-Martinez, Belen Tirado-Rodriguez, Angelica G Rocha-Lopez, Daniel Hernandez-Cueto, Sandra G Sánchez-Ceja, Berenice Alcala-Mota-Velazco, Anel Gomez-Garcia and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mayra Montecillo-AguadoUnidad de Investigación en Enfermedades Oncológicas, Hospital Infantil de México, Federico Gómez, Ciudad de México 06720, Mexico.
Giovanny Soca-ChafreUnidad de Investigación en Enfermedades Oncológicas, Hospital Infantil de México, Federico Gómez, Ciudad de México 06720, Mexico.ORCID 0000-0003-3985-9149
Gabriela Antonio-AndresUnidad de Investigación en Enfermedades Oncológicas, Hospital Infantil de México, Federico Gómez, Ciudad de México 06720, Mexico.
Mario Morales-MartinezUnidad de Investigación en Enfermedades Oncológicas, Hospital Infantil de México, Federico Gómez, Ciudad de México 06720, Mexico.
Belen Tirado-RodriguezUnidad de Investigación en Enfermedades Oncológicas, Hospital Infantil de México, Federico Gómez, Ciudad de México 06720, Mexico.
Angelica G Rocha-LopezDivisión de Estudios de Posgrado, Facultad de Ciencias Médicas y Biológicas Dr. Ignacio Chávez, Universidad Michoacana de San Nicolás de Hidalgo (UMSNH), Morelia 58060, Mexico.
Daniel Hernandez-CuetoUnidad de Investigación en Enfermedades Oncológicas, Hospital Infantil de México, Federico Gómez, Ciudad de México 06720, Mexico.
Sandra G Sánchez-CejaLaboratorio de Patología, Facultad de Químico Farmacobiología, Universidad Michoacana de San Nicolás de Hidalgo (UMSNH), Morelia 58060, Mexico.
Berenice Alcala-Mota-VelazcoDepartamento de Patología, Facultad de Odontología, Universidad Michoacana de San Nicolás de Hidalgo (UMSNH), Morelia 58060, Mexico.
Anel Gomez-GarciaCentro de investigación Biomédica de Michoacán, División de Investigación Clínica, Instituto Mexicano del Seguro Social, Morelia 58060, Mexico.ORCID 0000-0002-9158-1095
Sergio Gutiérrez-CastellanosDivisión de Estudios de Posgrado, Facultad de Ciencias Médicas y Biológicas Dr. Ignacio Chávez, Universidad Michoacana de San Nicolás de Hidalgo (UMSNH), Morelia 58060, Mexico.
Sara Huerta-YepezUnidad de Investigación en Enfermedades Oncológicas, Hospital Infantil de México, Federico Gómez, Ciudad de México 06720, Mexico.

Funding

Fondos Federales HIM/2017/114 SSA 1431.
6 · The paper itself

Abstract

Breast cancer (BC) is the most common cancer in women, with incidence rates increasing globally in recent years. Therefore, it is important to find new molecules with prognostic and therapeutic value to improve therapeutic response and quality of life. The polyunsaturated fatty acids (PUFAs) metabolic pathway participates in various physiological processes, as well as in the development of malignancies. Although aberrancies in the PUFAs metabolic pathway have been implicated in carcinogenesis, the functional and clinical relevance of this pathway has not been well explored in BC. To evaluate the clinical significance of soluble epoxide hydrolase (EPHX2) expression in Mexican patients with BC using tissue microarrays (TMAs) and digital pathology (DP). Immunohistochemical analyses were performed on 11 TMAs with 267 BC samples to quantify this enzyme. Using DP, EPHX2 protein expression was evaluated solely in tumor areas. The association of EPHX2 with overall survival (OS) was detected through bioinformatic analysis in public databases and confirmed in our cohort via Cox regression analysis. Clear nuclear expression of EPHX2 was identified. Receiver operating characteristics (ROC) curves revealed the optimal cutoff point at 2.847062 × 10

Indexed as

Biomarkers, TumorBreast NeoplasmsEpoxide HydrolasesAdultAgedAged, 80 and overCell NucleusFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMiddle AgedPrognosisROC CurveUp-RegulationBiomarkers, TumorEPHX2 protein, humanEpoxide Hydrolasesbreast cancer (BC)digital pathology (DP)overall survival (OS)soluble epoxide hydrolase (EPHX2)tissue microarray (TMA)

Identifiers

PMID39125591
PMCPMC11312095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.